ERBB2 and breast carcinoma: On the other hand, LM are becoming more common in patients with HER2+ subtypes of breast cancer, possibly as a result of advances in systemic anti‐HER2 therapy over the last decade, which have resulted in prolonged metastatic survival and better systemic disease control.14